The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: * are 18 years old or above and have mRCC * took medicines that use the bodies immunity to fight against cancer as their first choice of treatment * took other medicines after taking the above first choice of treatment This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include: * the length of time between the start of a patient's treatment and the end of treatment * the length of time between the start of treatment and death * physician assessment of a patient's response to treatment We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Demographical characteristics
Timeframe: From Time of Initiation of First-line (1L) Immuno-oncology (IO) combination therapy to death (up to 60 months)
Date of mRCC diagnosis
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Prior nephrectomy status
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Date of nephrectomy (if applicable)
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Tumor characteristics
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
IMDC risk score
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Number of lines of therapy received by each patient
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Treatment agents received at each line of therapy
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Duration of each line of therapy
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Time from discontinuation of previous line of therapy to initiation of subsequent line of therapy
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Reason for discontinuation for each line of therapy
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Time to treatment discontinuation (TTD)
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Time to next treatment (TTNT)
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Physician-assessed best response
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)
Overall survival
Timeframe: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)